XML 31 R24.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Collaboration and License Agreements - Additional Information 2 (Detail) (USD $) | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended
--- | --- | --- | --- | ---
Jan. 31, 2013 Molecule | Jun. 30, 2014 | Jun. 30, 2013 | Jun. 30, 2014 | Jun. 30, 2013 | Dec. 31, 2013
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
License grant fees |  | $ 15,000,000 |  | $ 15,000,000 |  |
Clinical milestone payments |  | 5,000,000 |  | 5,000,000 |  |
Deferred revenue under agreement |  | 20,684,000 |  | 20,684,000 |  | 20,267,000
Gilead [Member] |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Collaboration agreement date |  |  |  | January 2013 |  |
Commercialization of molecules | 4 |  |  |  |  |
License grant fees | 7,500,000 |  |  |  |  |
Expected period of development |  |  |  |  |  | 21 months
Recognized revenue under agreement |  | 2,300,000 | 2,000,000 | 4,500,000 | 3,700,000 |
Deferred revenue under agreement |  | 900,000 |  | 900,000 |  | 3,600,000
Gilead [Member] | Minimum [Member] |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Regulatory and sales milestone | 240,000,000 |  |  |  |  |
Gilead [Member] | Maximum [Member] |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Regulatory and sales milestone | 250,000,000 |  |  |  |  |
Gilead [Member] | Pre-Clinical Milestones [Member] | Minimum [Member] |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Clinical milestone payments | 20,000,000 |  |  |  |  |
Gilead [Member] | Pre-Clinical Milestones [Member] | Maximum [Member] |  |  |  |  |  |
License And Collaboration Agreements [Line Items] |  |  |  |  |  |
Clinical milestone payments | $ 25,000,000 |  |  |  |  |

X
- Definition Aggregate potential clinical milestone payments available to be earned under collaboration agreement. + References No definition available. + Details
Name: | mgnx_AdditionalClinicalMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional clinical, regulatory and sales milestone payments under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalClinicalRegulatoryAndSalesMilestonePaymentsUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Additional license grant fees under agreement. + References No definition available. + Details
Name: | mgnx_AdditionalLicenseGrantFeesUnderAgreement
Namespace Prefix: | mgnx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Collaboration and license agreement entered date. + References No definition available. + Details
Name: | mgnx_CollaborationAndLicenseAgreementEnteredDate
Namespace Prefix: | mgnx_
Data Type: | us-types:dateStringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | mgnx_LicenseAndCollaborationAgreementsLineItems
Namespace Prefix: | mgnx_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of molecules to be developed and commercialized as per collaborations. + References No definition available. + Details
Name: | mgnx_NumberOfMoleculesToBeDevelopedAndCommercializedAsPerCollaborations
Namespace Prefix: | mgnx_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment recognition period. + References No definition available. + Details
Name: | mgnx_UpfrontPaymentRecognitionPeriod
Namespace Prefix: | mgnx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=28358313&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 13 -Section A + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(e)) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_LicensesRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration